Westmount Partners LLC Sells 4,984 Shares of Illumina, Inc. $ILMN

Westmount Partners LLC decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.4% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 35,119 shares of the life sciences company’s stock after selling 4,984 shares during the quarter. Illumina comprises about 1.1% of Westmount Partners LLC’s portfolio, making the stock its 18th largest holding. Westmount Partners LLC’s holdings in Illumina were worth $4,329,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in ILMN. Elyxium Wealth LLC purchased a new position in Illumina during the 4th quarter valued at approximately $25,000. Board of the Pension Protection Fund purchased a new position in Illumina in the fourth quarter worth about $26,000. Creative Capital Management Investments LLC raised its position in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. bought a new position in shares of Illumina during the 4th quarter valued at approximately $26,000. Finally, Laurel Wealth Advisors LLC bought a new stake in Illumina in the fourth quarter worth $26,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the sale, the chief accounting officer directly owned 14,946 shares in the company, valued at $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,154 shares of company stock valued at $155,600,208 over the last quarter. 2.90% of the stock is owned by insiders.

Analyst Ratings Changes

ILMN has been the topic of several analyst reports. Guggenheim upped their price target on shares of Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a report on Monday, June 1st. Barclays lifted their price objective on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a report on Friday, May 1st. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Citigroup raised their price target on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Finally, Royal Bank Of Canada assumed coverage on shares of Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $142.12.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $161.93 on Friday. The company has a 50 day simple moving average of $145.20 and a two-hundred day simple moving average of $136.16. The stock has a market cap of $24.50 billion, a price-to-earnings ratio of 29.44, a PEG ratio of 3.03 and a beta of 1.50. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $177.22.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the business earned $0.97 earnings per share. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.